The study will see advanced liver tumours infected with the flu-like virus in order to attack and kill cancerous cells, while avoiding harm to healthy tissue.
Dr Tony Dhillon, who is a medical oncologist and leading the study at the Trust, said the results could be ‘potentially game changing’ for patients who have been told their liver cancer is inoperable.
Currently patients with advanced liver cancer are treated with daily tablets, which only slow the growth of the cancer.
The trial will see a small amount of the chemical altered virus injected into the tumour during a single appointment.
The virus will work by getting inside the tumour’s cancerous cells and replicating. Eventually the cells will become so full that they will burst, allowing the infection to spread to adjacent cells.
It is also hoped that the virus will also be able to penetrate tumours that have spread throughout the body.
Participants should only receive mild, flu like side effects.
Royal Surrey is the first centre in the UK to open the study, which hopes to recruit some 500 participants worldwide.
The trial will be randomised, which means half of the patients will receive the injection as well as the tablets, while the other half continue on just the tablets.
The findings will explore the effects of the virus on survival of this group of patients compared to the existing treatment.
A similar study is already being trialled in patients with skin cancer, although it is too early to see any clear results.
Dr Dhillon said: “This clinical trial is an exciting step forward to help find new ways of treating cancer.
“These novel approaches are needed to advance treatment, particularly in liver cancer, as the standard care has not changed in 11 years.
“While this treatment is still in its infancy, it could be potentially game changing for a group of patients who may have less than 12 months to live.”
Any patient’s with advanced liver cancer interested in taking part in the study should email firstname.lastname@example.org.